Conference Coverage

Nearly two-thirds of gynecologic oncology respondents experienced sexual harassment


 

REPORTING FROM ASCO 2019

– Nearly two-thirds of more than 400 U.S.-based physician members of the Society of Gynecologic Oncology who participated in a recent survey reported experiencing sexual harassment in training or practice.

Notably, of the 255 women and 147 men who responded, 71% and 51%, respectively, reported such sexual harassment – and only 15% overall reported it to officials, Marina Stasenko, MD, reported at the annual meeting of the American Society of Clinical Oncology.

The survey also addressed gender-based discrimination and disparities, including respondents’ views on pay disparities. In this video interview, Dr. Stasenko, a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center, New York, discusses the findings, their implications and context in this age of #MeToo and #TimesUp, and potential approaches to addressing the ongoing problem and the concerns victims have about reporting harassment.

“We need to start by setting an example, saying these things are not tolerated [and] put that into policy – really show folks how it can be reported and what is being done once that report is filed,” she said.

Dr. Stasenko reported having no disclosures.

SOURCE: Stasenko M et al. ASCO 2019, Abstract LBA10502.

Recommended Reading

For endometrial cancer, postop taxane/platinum competes with standard therapy
MDedge Hematology and Oncology
Pembrolizumab benefits some patients with advanced cervical cancer
MDedge Hematology and Oncology
In endometrial cancer and SUI, concomitant surgery improves outcomes
MDedge Hematology and Oncology
Decline in CIN2+ in younger women after HPV vaccine introduced
MDedge Hematology and Oncology
Lessons from KEYNOTE-158 and the role of R-CHOP
MDedge Hematology and Oncology
Vaginal brachytherapy more toxic than pelvic RT in endometrial carcinoma
MDedge Hematology and Oncology
Thrice yearly cytologic testing may best annual cervical screenings
MDedge Hematology and Oncology
Anomalous RT dose linked to lower survival in uterine cancer
MDedge Hematology and Oncology
Targeted sequencing panel IDs Lynch syndrome in women with/at risk for endometrial cancer
MDedge Hematology and Oncology
Cediranib may alter DNA repair capacity
MDedge Hematology and Oncology